Management of low blood pressure in ambulatory heart failure with reduced ejection fraction patients

被引:84
|
作者
Cautela, Jennifer [1 ]
Tartiere, Jean-Michel [2 ]
Cohen-Solal, Alain [3 ]
Bellemain-Appaix, Anne [4 ]
Theron, Alexis [5 ]
Tibi, Thierry [6 ]
Januzzi, James L., Jr. [7 ]
Roubille, Francois [8 ]
Girerd, Nicolas [9 ,10 ,11 ]
机构
[1] Aix Marseille I Univ, Hop Nord, Mediterranean Univ Cardiooncol Ctr MED ICO Ctr, Dept Cardiol,Heart Failure & Valvular Heart Dis U, Marseille, France
[2] Hop St Musse, Cardiol Dept, Toulon, France
[3] Paris Univ, Hop Lariboisiere, AP HP, CUMR S 942,MASCOT,Cardiol Dept, Paris, France
[4] Ctr Hosp Antibes Juan Pins, Cardiol Dept, Antibes, France
[5] Hop La Timone, Cardiothorac Surg Dept, Marseille, France
[6] Ctr Hosp Cannes, Cardiol Dept, Cannes, France
[7] Harvard Med Sch, Massachusetts Gen Hosp, Baim Inst Clin Res, Cardiol Div, Boston, MA 02115 USA
[8] Univ Montpellier, CHU Montpellier, CNRS, PhyMedExp,INSERM,Cardiol Dept, Montpellier, France
[9] Univ Lorraine, Vandoeuvre Nancy France Grp Choc, Ctr Invest Clin Plurithemat 1433,INSERM U1116, Inst Lorrain Coeur & Vaisseaux,Fac Med, Vandoeuvre Les Nancy, France
[10] F CRIN INI CRCT Cardiovasc & Renal Clin Trialists, Nancy, France
[11] CHRU Nancy, Inst Lorrain Coeur & Vaisseaux, Cardiol Dept, Nancy, France
关键词
Hypotension; Heart failure; Beta-blocker; Angiotensin-converting enzyme inhibitor; Angiotensin receptor blocker; Angiotensin receptor-neprilysin inhibitor; Mineralocorticoid receptor antagonist; Diuretics; LEFT-VENTRICULAR DYSFUNCTION; PULSE PRESSURE; SACUBITRIL/VALSARTAN LCZ696; PROGNOSTIC VALUE; DOUBLE-BLIND; SURVIVAL; MORTALITY; BLOCKER; ENALAPRIL; CARVEDILOL;
D O I
10.1002/ejhf.1835
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Low blood pressure is common in patients with heart failure and reduced ejection fraction (HFrEF). While spontaneous hypotension predicts risk in HFrEF, there is only limited evidence regarding the relationship between hypotension observed during heart failure (HF) drug titration and outcome. Nevertheless, hypotension (especially orthostatic hypotension) is an important factor limiting the titration of HFrEF treatments in routine practice. In patients with signs of shock and/or severe congestion, hospitalization is advised. However, in the very frequent cases of non-severe and asymptomatic hypotension observed while taking drugs with a class I indication in HFrEF, European and US guidelines recommend maintaining the same drug dosage. In instances of symptomatic or severe persistent hypotension (systolic blood pressure < 90 mmHg), it is recommended to first decrease blood pressure reducing drugs not indicated in HFrEF as well as the loop diuretic dose in the absence of associated signs of congestion. Unless the management of hypotension appears urgent, a HF specialist should then be sought rather than stopping or decreasing drugs with a class I indication in HFrEF. If symptoms or severe hypotension persist, no recommendations exist. Our HF group reviewed available evidence and proposes certain steps to follow in such situations in order to improve the pharmacological management of these patients.
引用
收藏
页码:1357 / 1365
页数:9
相关论文
共 50 条
  • [41] Anesthetic management of kidney transplantation patients with heart failure with reduced ejection fraction
    Magkachi, Estherlyn
    Jocson, Roan
    TRANSPLANTATION, 2024, 108 (09) : 282 - 282
  • [42] Management of patients with diabetes and heart failure with reduced ejection fraction: An international comparison
    Arnold, Suzanne V.
    Yap, Jonathan
    Lam, Carolyn S. P.
    Tang, Fengming
    Tay, Wan T.
    Teng, Tiew H. K.
    McGuire, Darren K.
    Januzzi, James L.
    Fonarow, Gregg C.
    Masoudi, Frederick A.
    Kosiborod, Mikhail
    DIABETES OBESITY & METABOLISM, 2019, 21 (02): : 261 - 266
  • [43] Anesthetic management of kidney transplantation patients with heart failure with reduced ejection fraction
    Magkachi, Estherlyn
    Jocson, Roan
    TRANSPLANTATION, 2024, 108 (9S)
  • [44] Benzodiazepines in Patients with Heart Failure and Reduced Ejection Fraction
    Chuang, Chi
    Hsiao, Fu-Chih
    Cheng, Yu-Wen
    Lin, Chia-Pin
    Tung, Ying-Chang
    Wu, Chia-Tung
    Chen, Ching-Yen
    Chu, Pao-Hsien
    ACTA CARDIOLOGICA SINICA, 2022, 38 (05) : 573 - 583
  • [45] Hypertension in Patients with Heart Failure with Reduced Ejection Fraction
    Massimo Volpe
    Caterina Santolamazza
    Giuliano Tocci
    Current Cardiology Reports, 2016, 18
  • [46] Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
    Borghi, Claudio
    Cicero, Arrigo F. G.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (10): : 972 - 972
  • [47] Influence and management of diabetes mellitus in patients with heart failure with reduced ejection fraction
    Martinez-Mateo, V.
    Fernandez-Anguita, M.
    Cejudo, L.
    Paule, A. J.
    REVISTA CLINICA ESPANOLA, 2016, 216 (09): : 506 - 508
  • [48] Successful development of an ambulatory intravenous iron service for patients with heart failure with reduced ejection fraction
    Burchell, A. E.
    Nightingale, A. K.
    Baker, R. P.
    Mohammednoor, M. A. S.
    Pearson, B.
    Lightfoot, H.
    Donaldson, H.
    Greenwood, J.
    Ismail, Y.
    EUROPEAN JOURNAL OF HEART FAILURE, 2020, 22 : 182 - 182
  • [49] Heart Failure Preserved Ejection Fraction Patients Benefit From Heart Failure Reduced Ejection Fraction Guidelines
    Steahr, Gregg
    Kelly, Linda
    Moore, Meredith
    Hott, Brenda
    JOURNAL OF CARDIAC FAILURE, 2015, 21 (08) : S73 - S74
  • [50] Optimization of pharmacotherapies for ambulatory patients with heart failure and reduced ejection fraction is associated with improved outcomes
    Jarjour, Marilyne
    Leclerc, Jacinthe
    Bouabdallaoui, Nadia
    Ahnadi, Charaf
    Brouillette, Denis
    de Denus, Simon
    Fortier, Annik
    Garceau, Patrick
    Giraldeau, Genevieve
    Lepage, Serge
    Liszkowski, Mark
    O'Meara, Eileen
    Parent, Marie -Claude
    Racine, Normand
    Tremblay-Gravel, Maxime
    White, Michel
    Rouleau, Jean-Lucien
    Ducharme, Anique
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2023, 370 : 300 - 308